An important and interesting trial from our SAKK network writes Prof. Sacha Rothschild, Chefarzt Zentrum für Onkologie & Hämatologie Kantonsspital Baden, in a LinkedIn post:
According to Rothschild, frail and elderly patients are often underrepresented in clinical trials, and there is a lack of scientific evidence on how to treat tumor patients with poor performance status properly. With the trial SAKK 19/17, the SAKK study shows that patients with metastatic NSCLC and PD-L1 expression of ≥25%, who have a poor performance status (PS2) and do not qualify for platinum-based combination therapy, benefit from monotherapy with a checkpoint inhibitor with appropriate clinical selection. Rothschild congratulates Michael Mark and the whole SAKK Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung team (Alfredo Addeo, Sabrina Chiquet, Martina Schneider, Karin Ribi, Roger von Moos, Markus Joerger MD-PhD ClinPharm) for their efforts!